by James Smith | Mar 7, 2016
Post by James Smith and Mackenna Roberts. Ms. Roberts is an English-qualified lawyer, trained bioethicist and strategic adviser for the commercialization of emerging biomedical technologies and is widely published on how the law should govern cutting-edge medical...
by Nicole Kuchinsky | Feb 29, 2016
Japan is making bold moves to redefine how cell therapies make it to market, and the world is taking notice. In late January, the Japan External Trade Organization (JETRO) collaborated with the Centre for Commercialization of Regenerative Medicine (CCRM) to host a...
by Mark Curtis | Dec 28, 2015
For those of you that missed ISCT’s recent webinar on manufacturing, needle-to-needle logistics and reimbursement, below is a brief re-cap of the key points on the reimbursement section that I provided. The presentation, including audio, should be available free on...
by Stacey Johnson | Nov 27, 2015
To some people, November is now Movember. That is testament to how successful and pervasive this campaign for men’s health – especially prostate cancer – has become. (Blogger Sara Nolte has also chosen to write about prostate cancer during Movember.) Last month the...
by David Kent | Nov 16, 2015
The United Kingdom has begun its foray into using cells derived from human embryonic stem cells (ESCs) in clinical settings. I have to admit I was surprised that following coverage on the BBC and in The Guardian, there was virtually no anti-ESC protesting to be found,...
Comments